Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): A multi-arm, multistage randomized controlled trial

BJU International

Volumn 103, Issue 4, 2009, Pages 464-469

  James, Nicholas D ^a   Sydes, Matthew R ^b,h   Clarke, Noel W ^c   Mason, Malcolm D ^d   Dearnaley, David P ^e   Anderson, John ^f   Popert, Richard J ^b   Sanders, Karen ^b   Morgan, Rachel C ^b   Stansfeld, Jim ^g   Dwyer, John ^g   Masters, John ^g   Parmar, Mahesh K B ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

Celecoxib; Docetaxel; Hormone therapy; Prostate cancer; Randomized controlled trial; Zoledronic acid

Indexed keywords

ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; CLODRONIC ACID; DOCETAXEL; EPIRUBICIN; MITOXANTRONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; ROFECOXIB; ZOLEDRONIC ACID;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; LIVER DYSFUNCTION; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PYRAZOLES; RISK FACTORS; SULFONAMIDES; TAXOIDS; TREATMENT OUTCOME;

EID: 59249100332     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08034.x     Document Type: Review

References (32)

1. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 351 : 1502 12
2. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 351 : 1513 20
3. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008 26 : 242 5
4. Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock AI. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 Study. Clin Cancer Res 2008 14 : 2763 7
5. Wang J, Halford S, Rigg A, Roylance R, Lynch M, Waxman J. Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Int 2000 86 : 675 80
6. Pummer K, Lehnert M, Stettner H, Hubmer G. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 1997 32 (Suppl. 3 81 5
7. Dearnaley DP, Sydes MR, Mason MD et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003 95 : 1300 11
8. Mason MD, Sydes MR, Glaholm J et al. Oral sodium clodronate for nonmetastatic prostate cancer - results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 2007 99 : 765 76
9. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002 94 : 1458 68
10. Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004 96 : 879 82
11. NCCF. Prostate cancer: diagnosis and treatment. National Collaborating Centre for Cancer (2nd Floor, Front Suite, Park House, Greyfriars Road, Cardiff, CF10 3AF) at Velindre NHS Trust, Cardiff, Wales 2008
12. Scottish Medicines Consortium. Advice: Zoledronic Acid. SMC, 2004. Available at: http://www.scottishmedicines.org.uk/smc/
13. Boissier S, Ferreras M, Peyruchaud O et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000 60 2949 54
14. Boissier S, Magnetto S, Frappart L et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997 57 : 3890 4
15. Fournier P, Boissier S, Filleur S et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002 62 : 6538 44
16. Magnetto S, Boissier S, Delmas PD, Clezardin P. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999 83 : 263 9
17. Montague R, Hart CA, George NJ, Ramani VA, Brown MD, Clarke NW. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of zoledronic acid in prostate cancer. Eur Urol 2004 46 : 389 401
18. Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998 77 : 511 5
19. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 2000 7 : 169 70
20. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clinic Proc 2002 77 : 219 25
21. Khor LY, Bae K, Pollack A et al. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol 2007 8 : 912 20
22. James N. Cyclooxygenase-2 inhibitors and prostate cancer. Lancet Oncol 2007 8 : 859 60
23. Brubaker KD, Brown LG, Vessella RL, Corey E. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 2006 6 : 15
24. Witters LM, Crispino J, Fraterrigo T, Green J, Lipton A. Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol 2003 26 : S92 7
25. Parmar MKB, Barthel FMS, Sydes MR et al. Speeding up the Evaluation of New Agents in Cancer. J Natl Cancer Institute 2008 100 : 1204 14
26. Bookman MA. GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with Gemcitabine (G), PEG-liposomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: abstract 5002)
27. Seymour MT, Maughan TS, Ledermann JA et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007 370 : 143 52
28. Oefelein MG, Agarwal PK, Resnick MI. Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. J Urol 2004 171 : 1525 8
29. Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989 321 : 419 24
30. Eisenberger MA, Blumenstein BA, Crawford ED et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998 339 : 1036 42
31. Eisenberger MA, Crawford ED, Wolf M et al. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036. Semin Oncol 1994 21 : 613 9
32. Sharifi N, Dahut WL, Steinberg SM et al. A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int 2005 96 : 985 9